Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population
The availability of a new 20-valent pneumococcal conjugate vaccine (PCV) makes it appropriate to assess its cost-effectiveness. This was evaluated by adopting the Italian National Health Service perspective, using a cost consequences Markovian model. The expected effects of vaccination with 20-valen...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/12/2032 |
| _version_ | 1797455040537952256 |
|---|---|
| author | Barbara Polistena Giancarlo Icardi Andrea Orsi Federico Spandonaro Roberto Di Virgilio Daniela d’Angela |
| author_facet | Barbara Polistena Giancarlo Icardi Andrea Orsi Federico Spandonaro Roberto Di Virgilio Daniela d’Angela |
| author_sort | Barbara Polistena |
| collection | DOAJ |
| description | The availability of a new 20-valent pneumococcal conjugate vaccine (PCV) makes it appropriate to assess its cost-effectiveness. This was evaluated by adopting the Italian National Health Service perspective, using a cost consequences Markovian model. The expected effects of vaccination with 20-valent PCV were compared with the administration of 13-valent PCV and 15-valent PCV. Assuming a 100% vaccination of cohorts aged 65–74 years, in the (lifetime) comparison between 20-valent PCV and 13-valent PCV, the former is dominant (lower cost for a better health outcome). A reduction in disease events was estimated: −1208 deaths; −1171 cases of bacteraemia; −227 of meningitis; −9845 hospitalised all-cause nonbacteremic pneumonia cases (NBP) and −21,058 non-hospitalised. Overall, in the Italian population, a total gain of 6581.6 life years and of 4734.0 QALY was estimated. On the cost side, against an increase in vaccinations costs (EUR +40.568 million), other direct health costs are reduced by EUR 48.032 million, with a net saving of EUR +7.464 million. The comparison between 20-valent PCV and 15-valent PCV results in an Incremental Cost-Effectiveness Ratio (ICER) of EUR 66 per life year gained and EUR 91 per QALY gained. The sensitivity analyses confirm the robustness of the results. We can conclude that the switch to 20-valent PCV is a sustainable and efficient investment. |
| first_indexed | 2024-03-09T15:45:50Z |
| format | Article |
| id | doaj.art-79f63ed44f1f4e6c91303cb87c4602b3 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T15:45:50Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-79f63ed44f1f4e6c91303cb87c4602b32023-11-24T18:31:29ZengMDPI AGVaccines2076-393X2022-11-011012203210.3390/vaccines10122032Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult PopulationBarbara Polistena0Giancarlo Icardi1Andrea Orsi2Federico Spandonaro3Roberto Di Virgilio4Daniela d’Angela5C.R.E.A. Sanità, Roma and University of Roma “Tor Vergata”, 00133 Rome, ItalyDepartment of Health Sciences (DISSAL), IRCCS Ospedale Policlinico San Martino, University of Genoa, 16132 Genova, ItalyDepartment of Health Sciences (DISSAL), IRCCS Ospedale Policlinico San Martino, University of Genoa, 16132 Genova, ItalyC.R.E.A. Sanità, University San Raffaele, 00166 Rome, ItalyPfizer Italia s.r.l., 00188 Rome, ItalyC.R.E.A. Sanità, Roma and University of Roma “Tor Vergata”, 00133 Rome, ItalyThe availability of a new 20-valent pneumococcal conjugate vaccine (PCV) makes it appropriate to assess its cost-effectiveness. This was evaluated by adopting the Italian National Health Service perspective, using a cost consequences Markovian model. The expected effects of vaccination with 20-valent PCV were compared with the administration of 13-valent PCV and 15-valent PCV. Assuming a 100% vaccination of cohorts aged 65–74 years, in the (lifetime) comparison between 20-valent PCV and 13-valent PCV, the former is dominant (lower cost for a better health outcome). A reduction in disease events was estimated: −1208 deaths; −1171 cases of bacteraemia; −227 of meningitis; −9845 hospitalised all-cause nonbacteremic pneumonia cases (NBP) and −21,058 non-hospitalised. Overall, in the Italian population, a total gain of 6581.6 life years and of 4734.0 QALY was estimated. On the cost side, against an increase in vaccinations costs (EUR +40.568 million), other direct health costs are reduced by EUR 48.032 million, with a net saving of EUR +7.464 million. The comparison between 20-valent PCV and 15-valent PCV results in an Incremental Cost-Effectiveness Ratio (ICER) of EUR 66 per life year gained and EUR 91 per QALY gained. The sensitivity analyses confirm the robustness of the results. We can conclude that the switch to 20-valent PCV is a sustainable and efficient investment.https://www.mdpi.com/2076-393X/10/12/2032vaccinesimmunizationcost consequencescost-effectivenesscost-utilities |
| spellingShingle | Barbara Polistena Giancarlo Icardi Andrea Orsi Federico Spandonaro Roberto Di Virgilio Daniela d’Angela Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population Vaccines vaccines immunization cost consequences cost-effectiveness cost-utilities |
| title | Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population |
| title_full | Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population |
| title_fullStr | Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population |
| title_full_unstemmed | Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population |
| title_short | Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population |
| title_sort | cost effectiveness of vaccination with the 20 valent pneumococcal conjugate vaccine in the italian adult population |
| topic | vaccines immunization cost consequences cost-effectiveness cost-utilities |
| url | https://www.mdpi.com/2076-393X/10/12/2032 |
| work_keys_str_mv | AT barbarapolistena costeffectivenessofvaccinationwiththe20valentpneumococcalconjugatevaccineintheitalianadultpopulation AT giancarloicardi costeffectivenessofvaccinationwiththe20valentpneumococcalconjugatevaccineintheitalianadultpopulation AT andreaorsi costeffectivenessofvaccinationwiththe20valentpneumococcalconjugatevaccineintheitalianadultpopulation AT federicospandonaro costeffectivenessofvaccinationwiththe20valentpneumococcalconjugatevaccineintheitalianadultpopulation AT robertodivirgilio costeffectivenessofvaccinationwiththe20valentpneumococcalconjugatevaccineintheitalianadultpopulation AT danieladangela costeffectivenessofvaccinationwiththe20valentpneumococcalconjugatevaccineintheitalianadultpopulation |